Literature DB >> 10828872

Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).

C Peters1, W Krivit.   

Abstract

Hunter syndrome is an X-linked metabolic storage disorder arising from deficiency of iduronate sulfatase enzyme activity. Despite the successful use of hematopoietic cell transplantation for a variety of lysosomal and peroxisomal storage diseases, limited benefit occurs following transplantation in either the severe or mild forms of Hunter syndrome. A brief ethical commentary is provided on the case of a boy with mucopolysaccharidosis IIB (ie the mild form) who received an unrelated umbilical cord blood transplant to improve his future quality of life. Bone Marrow Transplantation (2000).

Entities:  

Mesh:

Year:  2000        PMID: 10828872     DOI: 10.1038/sj.bmt.1702398

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  In utero transplantation of monocytic cells in cats with alpha-mannosidosis.

Authors:  Janis L Abkowitz; Kathleen M Sabo; Zhantao Yang; Charles H Vite; Laurence E Shields; Mark E Haskins
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

Review 2.  New prospects for the treatment of lysosomal storage diseases.

Authors:  Raphael Schiffmann; Roscoe O Brady
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Recent trends in mucopolysaccharidosis research.

Authors:  Hiroshi Kobayashi
Journal:  J Hum Genet       Date:  2018-11-19       Impact factor: 3.172

Review 4.  Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases.

Authors:  William Krivit
Journal:  Springer Semin Immunopathol       Date:  2004-09-25

Review 5.  Adult stem cells and their trans-differentiation potential--perspectives and therapeutic applications.

Authors:  Sabine Hombach-Klonisch; Soumya Panigrahi; Iran Rashedi; Anja Seifert; Esteban Alberti; Paola Pocar; Maciej Kurpisz; Klaus Schulze-Osthoff; Andrzej Mackiewicz; Marek Los
Journal:  J Mol Med (Berl)       Date:  2008-07-16       Impact factor: 4.599

6.  Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.

Authors:  Francyne Kubaski; Hiromasa Yabe; Yasuyuki Suzuki; Toshiyuki Seto; Takashi Hamazaki; Robert W Mason; Li Xie; Tor Gunnar Hugo Onsten; Sandra Leistner-Segal; Roberto Giugliani; Vũ Chí Dũng; Can Thi Bich Ngoc; Seiji Yamaguchi; Adriana M Montaño; Kenji E Orii; Toshiyuki Fukao; Haruo Shintaku; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-01       Impact factor: 5.742

7.  Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model.

Authors:  S Martino; C Cavalieri; C Emiliani; D Dolcetta; M G Cusella De Angelis; V Chigorno; G M Severini; K Sandhoff; C Bordignon; S Sonnino; A Orlacchio
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

8.  Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche.

Authors:  Tian Li; Yaojiong Wu
Journal:  Bone Marrow Res       Date:  2011-09-22

Review 9.  Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.

Authors:  David Ah Whiteman; Alan Kimura
Journal:  Drug Des Devel Ther       Date:  2017-08-23       Impact factor: 4.162

10.  Assessment of Activity of Daily Life in Mucopolysaccharidosis Type II Patients with Hematopoietic Stem Cell Transplantation.

Authors:  Yasuyuki Suzuki; Madeleine Taylor; Kenji Orii; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Diagnostics (Basel)       Date:  2020-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.